Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB])

被引：6
|
作者：
Phillips, Heidi
Sandmann, Thomas
Li, Congfen
Cloughesy, Timothy Francis
Chlnot, Olivier L.
Wick, Wolfgang
Nishikawa, Ryo
Mason, Warren P.
Henriksson, Roger
Saran, Frank
Lai, Albert
Moore, Nicola
Hegde, Priti S.
Abrey, Lauren E.
Bourgon, Richard
Garcia, Josep
Bais, Carlos
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Aix Marseille, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
[4] Heidelberg Univ, Neurooncol, Med Ctr, Heidelberg, Germany
[5] Saitama Med Univ, Saitama, Japan
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Reg Canc Ctr Stockholm Gotland, Stockholm, Sweden
[8] Royal Marsden NHS Fdn Trust, Surrey, England
[9] UCLA Neurooncol Program, Los Angeles, CA USA
[10] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2001
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Phillips, Heidi
    Sandmann, Thomas
    Li, Congfen
    Cloughesy, Timothy
    Chinot, Olivier L.
    Wick, Wolfgang
    Nishikawa, Ryo
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Lai, Albert
    Moore, Nicola
    Hegde, Priti
    Abrey, Lauren
    Bourgon, Richard
    Garcia, Josep
    Bais, Carlos
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [2] Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)
    Nishikawa, Ryo
    Saran, Frank
    Mason, Warren
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Henriksson, Roger
    Hilton, Magalie
    Garcia, Josep
    Vogt, Tobias
    Pallaud, Celine
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from AVAglio
    Chinot, O.
    Cloughesy, T.
    Henriksson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Wick, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S774 - S775
  • [4] AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
    Chinot, O. L.
    Rouge, T. de la Motte
    Moore, N.
    Zeaiter, A.
    Das, A.
    Phillips, H.
    Modrusan, Z.
    Cloughesy, T.
    [J]. ADVANCES IN THERAPY, 2011, 28 (04) : 334 - 340
  • [5] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    O. L. Chinot
    T. de La Motte Rouge
    N. Moore
    A. Zeaiter
    A. Das
    H. Phillips
    Z. Modrusan
    T. Cloughesy
    [J]. Advances in Therapy, 2011, 28 : 334 - 340
  • [6] Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Henriksson, Roger
    Bottomley, Andrew
    Mason, Warren
    Saran, Frank
    Wick, Wolfgang
    Nishikawa, Ryo
    Cloughesy, Timothy Francis
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba Ariela
    Hilton, Magalie
    Guijarro, Ana Maria Abajo
    Ravelo, Arliene
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
    Chinot, O. L.
    Wick, W.
    Saran, F.
    Mason, W. P.
    Henriksson, R.
    Nishikawa, R.
    Zeaiter, A. H.
    Moore, N.
    Das, A.
    Cloughesy, T. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) pies radiotherapy (RI) phis temozolomide (T) for newly diagnosed glioblastoma (GB)
    Wick, Wolfgang
    Chinot, Olivier L.
    Mason, Warren P.
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Revil, Cedric
    Kerloeguen, Yannick
    Cloughesy, Timothy Francis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RI) in newly diagnosed glioblastoma: Final results from AVAglio
    Wick, W.
    Cloughesy, T.
    Henrikkson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Chinot, O.
    [J]. ONKOLOGIE, 2013, 36 : 94 - 94
  • [10] Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
    Schiff, David
    Huse, Jason
    Wen, Patrick
    [J]. NEURO-ONCOLOGY, 2014, 16 (06) : 769 - 769
12345